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Letters e153etanercept, she experienced aggravation of the
psoriasis and psoriatic arthritis but refused other
treatments except nonsteroidal anti-inflammatory
drugs and topical betamethasone/calcipotriol.
Tumor necrosis factor (TNF)-alfa receptor
blockers are great advances in the treatment of
psoriasis and psoriatic arthritis. The immune
regulation of TNF-alfa has been highly controversial
regarding its risk in carcinogenesis. Kimball et al4
recently reported that there was little difference in
rates of lymphomas among different treatment
methods such as nonbiologic systemics, etanercept,
other TNF-alfa receptor blockers, and phototherapy.
To our knowledge, no reports have shown an
increased risk of lymphoma in patients using
etanercept.5 However, in patients with chronic
inflammatory disease and a history of long-term
use of immunosuppressive agents such as MTX or
cyclosporine, the synergetic effect of TNF-alfa
inhibitors and conventional immune modulators
may increase the risk of developing malignancy. As
TNF-alfa inhibitor use becomes more popular, this
case suggests the need for close observation to
identify the potential long-term risks associated
with chronic immune modulation.
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To the Editor: Immature neutrophils in the peripheral
circulation (bandemia) are an infrequently reported
finding in drug hypersensitivity syndrome (DHS).1-3
We report a case of DHSwith bandemia that resolved
after withdrawal of the offending medication and
initiation of prednisolone.
A previously healthy, school-aged girl was
admitted to the hospital with a 2-day history of fever,
facial edema, cervical lymphadenopathy, and a
morbilliform eruption that started on the face and
progressed caudally. The rash and fever developed
after 6 days of trimethoprim-sulfamethoxazole
(TMP-SMX) therapy for an uncomplicated urinary
tract infection. She denied ocular pain, dysphagia,
odynophagia, dysuria, and painful skin. Physical
examination revealed an ill-appearing African
American child with a temperature of 39.98C, mild
tachycardia, and tachypnea. A blanching morbilli-
form eruption was noted on her face, trunk, and
extremities with significant facial edema and sub-
centimeter, nontender cervical lymphadenopathy.
Mucosal surfaces were spared. Laboratory values
are listed in Table I. Blood culture revealed negative
findings, as did repeated urinalysis and urine culture.
Human herpesvirus-6 quantitative polymerase chain
reaction was positive at 300 copies/L. Epstein-Barr
virus serologies showed no evidence of current or
previous infection.
Although the patient’s eosinophils were within
normal reference range upon admission, the constel-
lation of clinical and laboratory findings (morbilli-
form eruption with facial edema, fever, elevated liver
enzymes and creatinine, and atypical lymphocytosis
after administration of TMP-SMX) was suggestive of
DHS. TMP-SMX was immediately discontinued, and
prednisolone (1 mg/kg/d) was initiated, in addition
to acetaminophen and maintenance intravenous
fluids. After 1 day of therapy, her eruption had
improved considerably, with normalization of her
vital signs. Her repeated complete blood cell
count on hospital day 2 demonstrated reduction
of peripheral bands to 3%, normalization of serum
Table I. Key laboratory values on admission
Laboratory component (normal value)
Values on
admission
Values 1 d after discontinuation
of 16-d corticosteroid taper
Values after a total 31 d
of corticosteroid treatment
White blood cell count (4.27-11.40 3 103/L) 4.9 8.1 11.6
Bands (0%) 16 N/A N/A
Eosinophils (0.0%-4.0%) 2.0 0.0 1.0
Atypical lymphocytes (2%-3%) 8.7 N/A N/A
Platelets (199-367 3 103/L) 138 639 215
Hemoglobin (11.5-15.5 g/dL) 10.6 11.9 12.9
Urea nitrogen (5-17 mg/dL) 7 15 15
Creatinine (0.1-0.5 mg/dL) 0.8 0.5 0.60
Alkaline phosphatase (175-420 U/L) 111 174 151
Alanine aminotransferase (10-35 U/L) 44 194 42
Aspartate aminotransferase (15-40 U/L) 67 297 18
Gamma-glutamyltransferase (11-21 U/L) 25 30 17
C-reactive protein (0.0-0.9 mg/dL) 8.1 N/A N/A
N/A, Not available.
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test results. Within 1 day of discontinuing the
16-day taper of prednisolone, however, her
rash and fever recurred, and laboratory evaluation
revealed elevated liver enzymes (Table I).
Prednisolone (1 mg/kg/d) was reinitiated with
subsequent normalization of laboratory values
(Table I). The prednisolone was tapered after an
additional 3 weeks of therapy with no evidence of
recurrence.
Although the presence of bandemia is frequently
seen in systemic infection as a result of bone-marrow
activation, it is rarely reported in DHS.1-3 Our
patient’s rapid resolution with discontinuation of
TMP-SMX and initiation of prednisolone strongly
suggests that the bandemia was caused by DHS
rather than infection.
Various mechanisms causing blood dyscrasias in
DHS include cytotoxic antibody-mediated destruc-
tion, reversible inhibition of stem cell activity,
cessation of myeloid maturation, and induction of
cytokine-activated macrophages leading to the
development of hemophagocytosis syndrome.3,4
The complex inflammatory response and the
resultant cytokine storm, notably tumor necrosis
factor-alfa among others, can stimulate the bone
marrow to release immature neutrophils.5
Recognition of the constellation of clinical
findings suggestive of DHS is vital particularly
when bandemia is present, as failure to stop the
offending medication can lead to exacerbation of the
underlying hypersensitivity, with resultant multi-
system organ failure. Bands are most commonly
associated with infection, but this report confirms
that peripheral bands can also be associated with
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